{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:41Z","timestamp":1792513121126,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.acuroe.2025.501719","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T22:00:33Z","timestamp":1739484033000},"page":"501719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease"],"prefix":"10.1016","volume":"49","author":[{"given":"R.","family":"Pichler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.H.","family":"van Creij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ca\u00f1o-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.H.","family":"Tully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pyrgidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2025.501719_bib0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.acuroe.2025.501719_bib0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cncr.28416","article-title":"Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation","volume":"120","author":"Cohn","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.acuroe.2025.501719_bib0025","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0030","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501719_bib0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501719_bib0040","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501719_bib0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/geno.2000.6332","article-title":"Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors","volume":"69","author":"Wiedemann","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.acuroe.2025.501719_bib0050","first-page":"1","article-title":"Structural and functional diversity in the FGF receptor multigene family","volume":"60","author":"Johnson","year":"1993","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.acuroe.2025.501719_bib0055","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.2741\/3007","article-title":"The heparanome and regulation of cell function: structures, functions and challenges","volume":"13","author":"Ori","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.acuroe.2025.501719_bib0060","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1042\/BST20180004","article-title":"Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting","volume":"46","author":"Farrell","year":"2018","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"10.1016\/j.acuroe.2025.501719_bib0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/cells8060536","article-title":"FGF19-FGFR4 signaling in hepatocellular carcinoma","volume":"8","author":"Raja","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.acuroe.2025.501719_bib0070","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","article-title":"Current progress in cancer treatment by targeting FGFR signaling","volume":"20","author":"Du","year":"2023","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.acuroe.2025.501719_bib0075","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1349-7006.2008.00840.x","article-title":"Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins","volume":"99","author":"Gotoh","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.acuroe.2025.501719_bib0080","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1158\/0008-5472.CAN-09-3033","article-title":"Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification","volume":"70","author":"Dudka","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.acuroe.2025.501719_bib0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0095","first-page":"5068","article-title":"A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1","volume":"11","author":"Mohammadi","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0100","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2001-2-3-reviews3005","article-title":"Fibroblast growth factors","volume":"2","author":"Ornitz","year":"2001","journal-title":"Genome Biol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.acuroe.2025.501719_bib0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0115","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919890285","article-title":"Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors","volume":"11","author":"Casadei","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0120","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0125","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Erdafitinib","year":"2012"},{"key":"10.1016\/j.acuroe.2025.501719_bib0130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/14737140.2019.1671190","article-title":"Erdafitinib for the treatment of urothelial cancer","volume":"19","author":"Marandino","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.acuroe.2025.501719_bib0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.acuroe.2025.501719_bib0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev.biochem.75.103004.142657","article-title":"Tyrphostins and other tyrosine kinase inhibitors","volume":"75","author":"Levitzki","year":"2006","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.acuroe.2025.501719_bib0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.acuroe.2025.501719_bib0165","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0170","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.acuroe.2025.501719_bib0175","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.acuroe.2025.501719_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111859","article-title":"Genomic heterogeneity as a barrier to precision oncology in urothelial cancer","volume":"41","author":"Clinton","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.acuroe.2025.501719_bib0185","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.acuroe.2025.501719_bib0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.acuroe.2025.501719_bib0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2025.501719_bib0200","article-title":"The jsonlite package: a practical and consistent mapping between json data and r objects","author":"Ooms","year":"2014","journal-title":"arXiv preprint arXiv:1403.2805"},{"key":"10.1016\/j.acuroe.2025.501719_bib0205","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.acuroe.2025.501719_bib0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006643","article-title":"Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0215","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours","volume":"55","author":"van Oers","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0220","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0225","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40291-023-00647-0","article-title":"Urothelial bladder cancer: genomic alterations in fibroblast growth factor receptor","volume":"27","author":"Bou Zerdan","year":"2023","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.acuroe.2025.501719_bib0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0235","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.euo.2020.04.005","article-title":"Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive assessment from the updated results of the PURE-01 study","volume":"4","author":"Necchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0240","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.acuroe.2025.501719_bib0245","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2025.501719_bib0250","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0255","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.acuroe.2025.501719_bib0260","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0265","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.409","article-title":"Fierce-21: phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC)","volume":"37","author":"Necchi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0270","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4511","article-title":"FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis","volume":"37","author":"Siefker-Radtke","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS595","article-title":"Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1\/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2\/3 genetic alterations (GAs)","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0280","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4521","article-title":"Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib\/II FORT-2 study","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0285","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4511","article-title":"Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: a phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC)","volume":"41","author":"Grivas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0290","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): final results from the phase 2 Norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0295","doi-asserted-by":"crossref","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","article-title":"LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)","volume":"34","author":"Vilaseca","year":"2023","journal-title":"Ann Oncol"},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0300","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.503","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, high-risk non\u2013muscle-invasive bladder cancer (HR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: cohort 2 interim analysis results","volume":"41","author":"Catto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0305","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.504","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non\u2013muscle-invasive bladder cancer (IR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: Cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.501","article-title":"Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): preliminary safety results from a phase 2 study","volume":"40","author":"Koshkin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.acuroe.2025.501719_bib0315","article-title":"Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations","volume":"8","author":"Necchi","year":"2024","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.acuroe.2025.501719_bib0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clgc.2021.10.004","article-title":"Infigratinib in early-line and salvage therapy for FGFR3-altered metastatic urothelial carcinoma","volume":"20","author":"Lyou","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0325","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.acuroe.2025.501719_bib0330","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/JU.0000000000003928","article-title":"Phase 1b trial evaluating tolerability and activity of targeted fibroblast growth factor receptor inhibition in localized upper tract urothelial carcinoma","volume":"211","author":"Matin","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0335","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.ejca.2014.10.013","article-title":"Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma","volume":"50","author":"Milowsky","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acuroe.2025.501719_bib0340","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuroe.2025.501719_bib0345","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0350","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501719_bib0355","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","article-title":"Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer","volume":"35","author":"Catto","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501719_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149314","article-title":"Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells","volume":"691","author":"Zhang","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.acuroe.2025.501719_bib0365","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501719_bib0370","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS592","article-title":"FIGHT-205: phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)\u2014Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:09:14Z","timestamp":1748783354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2173578625000022"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501719","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501719","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEU.","name":"copyright","label":"Copyright"}],"article-number":"501719"}}